PTGS2 and breast carcinoma: This could be explained by “compensation” mechanisms such as a stronger activity of the Cox-2 promoter in A549 cells and/or a better performance of the 5/3-modified fiber in breast cancer cells compared to relatively CAR-positive A549 cells.